STAT+: European regulatory panel weighing against approval of Amylyx’s ALS therapy, company says

A European regulatory panel has taken a negative view of whether an ALS treatment from Amylyx Pharmaceuticals should win approval, the company said Tuesday.

May 31, 2023 - 20:00
STAT+: European regulatory panel weighing against approval of Amylyx’s ALS therapy, company says

LONDON — A European regulatory panel has taken a negative view of whether an ALS treatment from Amylyx Pharmaceuticals should win approval, the company said Tuesday, threatening the drug’s chances of entering the European market.

In a statement, Amylyx said it had learned that a European Medicines Agency’s committee “is trending toward a negative opinion” on the drug, AMX0035, after its May meeting last week.

The committee is expected to issue its formal opinion next month, a recommendation that then goes to the European Commission, which makes the final authorization decision. The commission typically follows the committee’s guidance.

Continue to STAT+ to read the full story…

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow